Fuzhou Hanbeken Biotechnology Co., Ltd. was established in April 2019. It is a high - tech enterprise specializing in the R & D, production and sales of medical diagnostic instruments for human body fluids, supporting reagents and consumables. The company's headquarters is located in Pushang Industrial Park, Cangshan District, Fuzhou City, Fujian Province, with a total construction area of 4,000 square meters, including an independent office area, standardized factory buildings and a 100,000 - class purification production workshop of 1,200 square meters.
The company has a professional R & D team with overseas - returned doctors and professional masters as technical backbones, and a senior management and marketing team with more than 20 years of industry experience. Adhering to the development concept of "pursuing excellence", the company has signed industry - university - research strategic cooperation agreements with provincial universities, actively innovates and serves the society. Now it has national leading R & D achievements in urine analysis test strips and chemiluminescent immunoassay, as well as a number of product patents. And in December 2021, it was approved as a National High - Tech Enterprise.
Hanbeken Biotechnology Co., Ltd. relies on modern cutting - edge technology and takes the responsibility of promoting the development of modern medical testing. It adheres to technological innovation, continuously understands and meets customer needs, improves service awareness, and strives to provide customers with high - quality products and professional services.
Development History
2019: The company was founded and obtained the production filing certificate for Class I medical devices (sheath fluid)
2020: Obtained the registration certificate for urine test strips and 10 national authorized patents.
2021: Recognized as a National High-Tech Enterprise, obtained 10 national authorized patents, and acquired the Class II Medical Device Production License.
2022: Passed the ISO 13485 system certification, obtained registration certificates for 17 Class II chemiluminescence products and the corresponding Medical Device Production License, as well as 10 national authorized patents.
2023: Obtained registration certificates for 3 Class III chemiluminescence products and 10 national authorized patents.
2024: The BK2200 Urine Analysis System obtained registration approval; the semi-automatic urine analyzers BK-200 and BK-500 obtained certificates; supporting urine reagents (calibration solutions) and other products also obtained certificates.
“We have been working hard to constantly promote process improvement and technological innovation. And we always committed to provide high-quality products.”
Contact us
- Unity
- Strive
- Innovation
- Proactivity
